Acadia Pharmaceuticals Inc
ACADNasdaqCIK 1070494HealthcareFiscal year ends Dec 31
Reports and events: 302 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2316:51 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-430596 |
| 2026-09-2417:11 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-401157 |
| 2026-09-1117:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-389400 |
| 2026-08-0518:12 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001193125-26-333243 |
| 2026-08-0416:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-332858 |
| 2026-05-2916:05 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-248242 |
| 2026-05-0719:50 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001193125-26-209731 |
| 2026-05-0616:50 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-209253 |
| 2026-05-0117:34 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-197957 |
| 2026-04-2418:05 ET | DEF 14A | Proxy statementPeriod 2026-05-29 | 0001193125-26-174163 |
| 2026-03-0520:56 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-26-092213 |
| 2026-02-2618:59 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001104659-26-020778 |
| 2026-02-2619:22 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001193125-26-072519 |
| 2026-02-2516:20 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-071674 |
| 2026-01-1315:58 ET | 8-K | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-011706 |
| 2025-11-0618:47 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001193125-25-267453 |
| 2025-11-0516:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-266959 |
| 2025-11-0316:23 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-25-262610 |
| 2025-08-0717:53 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0000950170-25-104295 |
| 2025-08-0616:18 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-104092 |
| 2025-06-1016:06 ET | 8-K | 8.01 Other events | 0001193125-25-138452 |
| 2025-05-2916:06 ET | 8-K | 5.07 Shareholder vote results | 0001193125-25-130620 |
| 2025-05-2016:31 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events | 0001193125-25-123175 |
| 2025-05-0821:15 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0000950170-25-066231 |
| 2025-05-0716:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-065672 |
| 2025-04-2516:49 ET | DEF 14A | Proxy statementPeriod 2025-05-29 | 0000950170-25-058827 |
| 2025-04-1616:15 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-25-082809 |
| 2025-02-2717:26 ET | 10-K | Annual reportPeriod 2024-12-31 | 0000950170-25-029253 |
| 2025-02-2616:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-027759 |
| 2024-12-1116:22 ET | 8-K | 2.01 Completion of an acquisition or disposition | 0001193125-24-275595 |
| 2024-11-2016:30 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-262556 |
| 2024-11-0717:41 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0000950170-24-122513 |
| 2024-11-0616:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-122322 |
| 2024-09-2316:34 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-223726 |
| 2024-08-0719:48 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0000950170-24-092163 |
| 2024-08-0616:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-091826 |
| 2024-05-2917:23 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001193125-24-149336 |
| 2024-05-0919:13 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0000950170-24-056077 |
| 2024-05-0816:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-055647 |
| 2024-04-2616:21 ET | DEF 14A | Proxy statementPeriod 2024-05-29 | 0000950170-24-049182 |
| 2024-03-1116:05 ET | 8-K | 8.01 Other events | 0001193125-24-064791 |
| 2024-02-2818:01 ET | 10-K | Annual reportPeriod 2023-12-31 | 0000950170-24-021473 |
| 2024-02-2716:16 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-021169 |
| 2024-01-3121:55 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001193125-24-019903 |
| 2023-11-2117:11 ET | 8-K | 8.01 Other events | 0001193125-23-281574 |
| 2023-11-0318:33 ET | 10-Q | Quarterly reportPeriod 2023-09-30 | 0000950170-23-058436 |
| 2023-11-0216:21 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-058254 |
| 2023-08-0319:29 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0000950170-23-037458 |
| 2023-08-0216:23 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-23-037216 |
| 2023-07-1816:01 ET | 8-K | 1.01 Entry into a material agreement; 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-23-188839 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:03 ET. Listed shows no prices and gives no investment advice.